Business Wire

IFF Presents “Learning Labs” Video Series to Demonstrate Potential of New Company

Share

IFF (NYSE: IFF) today introduced a new “Learning Labs” video series, featuring in-depth discussions with the leadership of the company’s segments and R&D function. Each video provides a comprehensive overview of IFF’s robust portfolio and enhanced capabilities following its recently completed merger with DuPont’s Nutrition and Biosciences (“N&B”) business. The complete “Learning Labs” series can be found here: ir.iff.com/events-presentations. In addition, IFF has also provided segment-level financial detail based on 2020 pro forma results.

“As a global industry leader of high-value consumer ingredients, we are pleased to provide a closer look into our capabilities, operational model and future growth potential,” said Andreas Fibig, IFF Chairman and CEO. “Stakeholder communication remains essential to IFF’s continued growth, and since combining with N&B, we have continued to explore new ways to meaningfully connect with our investors. The insights shared through our ‘Learning Labs’ series and detail provided in our 2020 pro forma segment financials is a testament to our commitment to continued transparency and greater comparability to peers.”

IFF 2020 Pro Forma Segment-Level Financial Results

To accompany the “Learning Labs” video series, IFF has provided additional detail on the financial performance, including sales and adjusted EBITDA metrics, for each of the company’s four segments on a 2020 pro forma basis.

Welcome to IFF

At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.

International Flavors & Fragrances Inc.

2020 Pro Forma Combined Reporting Segments (1)(2)

(Dollars in millions)

Q1
2020 (3)

Q2
2020

Q3
2020

Q4
2020

Pro Forma
FY 2020 (excl.
N&B Jan.) (3)

Pro Forma
FY 2020 (4)

Nourish Pro Forma Sales

1,276

1,450

1,418

1,488

5,632

5,887

Nourish Pro Forma Adjusted Operating EBITDA

255

303

275

257

1,090

1,153

as % of Pro Forma Sales

20%

21%

19%

17%

19%

20%

Scent Pro Forma Sales

541

475

525

524

2,064

2,064

Scent Pro Forma Adjusted Operating EBITDA

118

87

118

93

416

416

as % of Pro Forma Sales

22%

18%

22%

18%

20%

20%

Health & Biosciences Pro Forma Sales

427

588

579

572

2,166

2,353

Health & Biosciences Pro Forma Adjusted Operating EBITDA

131

181

172

149

634

680

as % of Pro Forma Sales

31%

31%

30%

26%

29%

29%

Pharma Solutions Pro Forma Sales

152

224

215

188

779

839

Pharma Solutions Pro Forma Adjusted Operating EBITDA

42

62

61

38

203

216

as % of Pro Forma Sales

28%

28%

28%

20%

26%

26%

% Change in Sales - 2020 vs. 2019 (5)

Q1 (3)

Q2

Q3

Q4

Reported

Currency
Neutral

Reported

Currency
Neutral

Reported

Currency
Neutral

Reported

Currency
Neutral

Nourish

3%

5%

(4)%

(1)%

(5)%

(3)%

—%

1%

Scent

4%

7%

(6)%

—%

4%

9%

4%

6%

Health & Biosciences

8%

11%

(4)%

(2)%

(1)%

—%

1%

—%

Pharma Solutions

9%

11%

6%

7%

2%

1%

(2)%

(4)%

Total

4%

7%

(4)%

—%

(2)%

—%

1%

1%

Pro Forma FY 2020
(excl. N&B Jan.) (3)

Pro Forma

FY 2020 (4)

Reported

Currency
Neutral

Reported

Currency
Neutral

Nourish

(2)%

—%

(2)%

—%

Scent

2%

5%

2%

5%

Health & Biosciences

—%

1%

—%

1%

Pharma Solutions

4%

3%

1%

1%

Total

—%

2%

(1)%

1%

_______________________

Note: Adjusted Operating EBITDA for each segment is defined as Income (Loss) Before Taxes before depreciation and amortization expense, interest expense, restructuring and other charges, net and certain non-recurring items. Additionally, all corporate expenses have been allocated to all of the reportable segments.

  1. The pro forma historical segment information has been presented for informational purposes only and is not necessarily indicative of what IFF's results of operations actually would have been, had the N&B transaction occurred on the dates indicated below. In addition, the pro forma historical segment information does not purport to project the future operating results of the Company.
  2. Dollar amounts may not foot due to rounding.
  3. The first quarter and Pro Forma FY 2020 (excl. N&B Jan.) show the combination of the historical results of IFF and N&B as if the N&B transaction had been consummated on February 1, 2020. Therefore, the first quarter and Pro Forma FY 2020 (excl. N&B Jan.) do not include the N&B business for the month of January 2020, which would allow comparability against the 2021 calendar year since the merger occurred on February 1, 2021. Total N&B Sales and Adjusted Operating EBITDA included in reportable segments for the month of January 2020 amounted to $502 million and $124 million, respectively.
  4. Pro Forma FY 2020 shows the combination of the historical results of IFF and N&B as if the N&B Transaction had been consummated on January 1, 2020. Therefore, Pro Forma FY 2020 includes a full twelve months of 2020 N&B and IFF results.
  5. Effective 2021, we calculate currency neutral growth by translating current year invoiced sale amounts at the average exchange rates used for the corresponding prior year period. Previously we calculated currency neutral numbers by comparing current year results to the prior year results restated at exchange rates in effect for the current year based on the currency of the underlying transaction.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Michael DeVeau
Chief Investor Relations & Communications Officer
212.708.7164
Michael.DeVeau@iff.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lattice Automate Solution Stack Accelerates Development of Industrial Automation Systems11.5.2021 20:00:00 CEST | Press release

Lattice Semiconductor Corporation (NASDAQ: LSCC), the low power programmable leader, today extended its portfolio of comprehensive low power FPGA-based solution stacks with the introduction of Lattice Automate™. The stack includes software tools, industrial IP cores, modular hardware development boards, and software-programmable reference designs and demos that simplify and accelerate implementation of applications like robotics, scalable multi-channel motor control with predictive maintenance, and real-time industrial networking. Intelligent industrial systems made possible by Automate will play a vital role in automating future smart factories, warehouses, and commercial buildings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005309/en/ Introducing the Lattice Automate solution stack for the accelerated development of industrial automation applications. (Graphic: Business Wire) Technology trends like the IoT and Ed

Esri and IBM Team Up to Take on Climate Change with Call for Code11.5.2021 19:23:00 CEST | Press release

Esri, the global leader in location intelligence, today announced it is joining the fourth annual Call for Code Global Challenge. Created by David Clark Cause and launched in partnership with IBM, United Nations Human Rights, and the Linux Foundation, Call for Code is designed to make an immediate and lasting global impact on humanitarian issues, using open-source-powered technology. In this year’s competition, software developers and innovators around the world will take on climate change with open-source software, including Red Hat OpenShift, IBM Cloud, IBM Watson, IBM Blockchain, and data from The Weather Company. Since Call for Code was launched in 2018, more than 400,000 developers and problem solvers across 179 nations have participated, creating more than 15,000 applications. This year’s competition focuses on three sub-themes related to combating climate change: water availability and consumption, food production and delivery, and economic production and consumption. The winnin

Experian Announces New Commitment to a Flexible Working Culture11.5.2021 18:26:00 CEST | Press release

Experian, the global information services company, has today announced a new global approach to work. The aim is to take the learnings from the experience of Covid-19 lockdown and create a working environment which suits everyone’s situation. Experian is committing to promote more individual choice by creating a new hybrid model, where employees will be encouraged to ‘work your way’. Through the lockdown, Experian moved its global operations to remote working with very limited disruption. Most employees will be offered increased flexibility, with the majority moving to a hybrid model, some working fully remotely, and some in the office. Experian – which operates in 45 countries around the world – believes this will continue to boost productivity and improve the work / life balance options for its 17,800 global employee base. What the Covid-19 crisis has reminded us, beyond everything else, is that we are all individuals living very different lives. That’s prompted Experian to go down t

SentinelOne is the Only Vendor to Score Highest Across All Three Gartner Critical Capabilities Use Cases11.5.2021 17:40:00 CEST | Press release

SentinelOne, the autonomous cybersecurity platform company, today announced that Gartner has positioned SentinelOne with the highest scores in all three use cases; Type A, B, & C in Gartner’s 2021 Critical Capabilities for Endpoint Protection Platforms report1. Out of the 19 vendors included in the report, SentinelOne is the only vendor that received the highest score across all three Critical Capabilities use cases: Customer use case Type A is focused on “lean forward” organizations that adopt new technologies very early in the adoption cycle. Customer use case Type B is focused on “overall value” by weighing the risks of the early use of new technology against the benefits. Customer use case Type C represents organizations that typically view technology as an expense or operational necessity and use it as a means to reduce costs. “We believe receiving the highest product score across all three customer use cases in the 2021 Critical Capabilities for Endpoint Protection Platforms vali

1E Challenges DEM Market to Deliver More, Launching New Unified eXperience Management Category11.5.2021 16:35:00 CEST | Press release

1E, innovators in endpoint management, today announced Unified eXperience Management (UXM), a new category that seeks to address the siloed approach inherent in tools in the Digital Experience Monitoring (DEM) space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005842/en/ 1E Tachyon Platform: Unified eXperience Management to improve the Digital Experience of all employees (Graphic: Business Wire) Due to the relative immaturity of the Digital Experience Management category, most tooling is focused on identifying and reporting on the scale of the problem, scoring, and issue identification. These tools create analytics silos that give insight, but are uncoupled from the automation technology that can actually improve end-user experience at an enterprise scale. Meanwhile, employees are becoming increasingly more frustrated, with 56% feeling dissatisfied with their IT experience. Organizations looking to improve the digit

Biorasi Receives ISO 9001:2015 Certification for Quality Management11.5.2021 16:30:00 CEST | Press release

Biorasi, a leading global full-service contract research organization (CRO), is proud to announce the achievement of ISO 9001:2015 certification. By earning this ISO accreditation, Biorasi has demonstrated dedication to the practice of quality assurance within the clinical trials industry and commitment to quality excellence for individual clinical studies. “ISO 9001:2015 certification is a big deal for Biorasi,” said Chris O’Brien, CEO at Biorasi. “It is a powerful, independent validation of the quality of our processes. It sends a message to potential sponsors across the globe that Biorasi cares deeply about quality. It tells them they can trust us.” Biorasi was presented with their ISO 9001:2015 certification on May 5, 2021, joining the ranks of other quality-focused organizations, including our preferred vendor, IBM Watson Health. “Our Quality Policy is driven by the fundamental understanding that patients and their families are affected by the decisions we make,” said Todd Brill,

Alvotech Seeks to End AbbVie’s Wrongful Monopoly on Humira and Bring Affordable Arthritis Treatment to U.S.11.5.2021 16:23:00 CEST | Press release

Alvotech today filed a federal lawsuit (Case 1:21-cv-00589) seeking to end the monopoly that pharmaceutical giant AbbVie has long-maintained on the adalimumab market, sold as Humira. Humira is the highest grossing prescription drug in the United States with over $16 billion in sales in 2020 (nearly $20Bn globally). Alvotech has developed a biosimilar (analogous to a generic) of Humira called AVT02, the first-filed biosimilar drug equal in strength to Humira’s latest formulation, which AbbVie markets as a high-concentration, pain-free drug. The company is also developing AVT02 as an interchangeable product and it expects results from its ongoing interchangeability study in Q2 of this year. AVT02 could save U.S. taxpayers and the overall healthcare system $8-10 billion annually. “Our new product will be a gamechanger that will provide consumers who are suffering from chronic pain with significant savings, and we look forward to bringing this drug onto the market as soon as possible,” sai